Literature DB >> 6327848

Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation.

K A Weigle, C Grose.   

Abstract

The sequence of antibody formation to molecularly defined varicella-zoster virus (VZV) proteins was examined during the course of chickenpox, quiescence, and subsequent VZV reactivation and reinfection. The first antibodies produced after primary VZV infection were to two virion envelope glycoproteins, gp66 and gp118 , and the nucleocapsid protein p155 . Within one to two months, antibodies to a greater array of viral proteins and glycoproteins were observed. Antibodies to the immunodominant viral proteins ( gp66 , gp118 , and p155 ) persisted for years after varicella and were, therefore, excellent markers of prior VZV infection. Subclinical VZV reinfection also was associated with transient rises in levels of the same polypeptide-specific antibodies as during primary disease. The immunoglobulin response to zoster appeared more rapidly than that to chickenpox or reinfection and was to the broadest complement of viral proteins, including the distinctive VZV polypeptide p32. These radioimmune-precipitation profiles could be subdivided into six different patterns characteristic of the following clinical states: acute- and convalescent-phase chickenpox, quiescence, acute- and convalescent-phase zoster, and postzoster quiescence.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327848     DOI: 10.1093/infdis/149.5.741

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140).

Authors:  E A Montalvo; C Grose
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

2.  Varicella zoster virus glycoprotein gpI is selectively phosphorylated by a virus-induced protein kinase.

Authors:  E A Montalvo; C Grose
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Structural analysis of the varicella-zoster virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide moieties.

Authors:  E A Montalvo; R T Parmley; C Grose
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Varicella-zoster virus p32/p36 complex is present in both the viral capsid and the nuclear matrix of the infected cell.

Authors:  W E Friedrichs; C Grose
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

5.  Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells.

Authors:  A R Hayward; O Pontesilli; M Herberger; M Laszlo; M Levin
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

6.  Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.

Authors:  J A Englund; A M Arvin; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

7.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

8.  Reactivity of varicella-zoster virus subunit antigens in enzyme-linked immunosorbent assay to sera from varicella, zoster, and herpes simplex virus infections.

Authors:  M Takayama
Journal:  Med Microbiol Immunol       Date:  1994-02       Impact factor: 3.402

9.  Comparative immunohistochemical study of herpes simplex and varicella-zoster infections.

Authors:  A F Nikkels; S Debrus; C Sadzot-Delvaux; J Piette; P Delvenne; B Rentier; G E Piérard
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques.

Authors:  Kristen Haberthur; Aubrey Kraft; Nicole Arnold; Byung Park; Christine Meyer; Mark Asquith; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.